X
X-Imaging
Providing full-process automation and intelligent comprehensive solutions from molecules to cells for biochemistry, medical medicine and safety inspection and testing
About X-Imaging
XImaging is a pioneering company specializing in AI-driven automation and intelligent solutions for the life sciences, pharmaceutical research, and diagnostics industries. The company operates in the high-tech sector, providing advanced robotic workstations, integrated systems, supporting instruments, and related consumables. XImaging's clientele includes pharmaceutical companies, research institutions, and diagnostic labs seeking to enhance their operational efficiency and safety standards.
The company's business model revolves around the development and deployment of automated systems that streamline laboratory processes, from food and pharmaceutical safety to synthetic biology. XImaging generates revenue through the sale of its cutting-edge equipment, customized solutions, and ongoing service contracts.
Key projects include the establishment of an AI-powered pharmaceutical research laboratory in China and an mRNA automated research lab, which significantly contribute to vaccine research and production. Additionally, XImaging has built a demonstration laboratory in Shanghai, adhering to ISO7 biological standards, to showcase its capabilities in life sciences and pharmaceutical research.
XImaging's commitment to innovation is evident in its comprehensive approach to laboratory automation, offering solutions that support single and multiple tasks, sequential optimization, and compatibility with both automated and manual operations. The company's systems are designed to be extensible and customizable, ensuring they meet the specific needs of each client.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Minhang District, China
- Employees
- 9
- Open positions
- 8
- Dealroom signal
- 25.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2023 | $14M | $55M | DNE Group · Shengshan Asset Management · Watson Capital Partners · Qingshuiwan Fund | ↗ |
| SEEDEquity / VC | Aug 2021 | $0 | — | Phoenix Tree Capital Partners | ↗ |
Growth signals
Latest recorded traffic for X-Imaging is 720 monthly website visits, up 33.3% over the last three months. X-Imaging's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Phoenix Tree Capital Partners
Series A4 investors entered at this stage
Shengshan Asset Management- DGDNE Group
- WPWatson Capital Partners
- QFQingshuiwan Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about X-Imaging on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See X-Imaging’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.